BR112023021561A2 - Compostos de carbóxi-benzimidazol moduladores de glp-1r - Google Patents
Compostos de carbóxi-benzimidazol moduladores de glp-1rInfo
- Publication number
- BR112023021561A2 BR112023021561A2 BR112023021561A BR112023021561A BR112023021561A2 BR 112023021561 A2 BR112023021561 A2 BR 112023021561A2 BR 112023021561 A BR112023021561 A BR 112023021561A BR 112023021561 A BR112023021561 A BR 112023021561A BR 112023021561 A2 BR112023021561 A2 BR 112023021561A2
- Authority
- BR
- Brazil
- Prior art keywords
- glp
- carboxy
- modulator
- benzimidazole compounds
- compounds
- Prior art date
Links
- RHXSYTACTOMVLJ-UHFFFAOYSA-N 1H-benzimidazole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=NC2=C1 RHXSYTACTOMVLJ-UHFFFAOYSA-N 0.000 title abstract 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title 1
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
compostos de carbóxi-benzimidazol moduladores de glp-1r. a presente invenção fornece agonistas de glp-1r, e composições, métodos, e kits dos mesmos. tais compostos são geralmente úteis para tratamento de uma doença ou condição mediada por glp-1r em um ser humano.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163177778P | 2021-04-21 | 2021-04-21 | |
US202163286475P | 2021-12-06 | 2021-12-06 | |
PCT/US2022/025364 WO2022225941A1 (en) | 2021-04-21 | 2022-04-19 | Carboxy-benzimidazole glp-1r modulating compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023021561A2 true BR112023021561A2 (pt) | 2023-12-19 |
Family
ID=81654570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023021561A BR112023021561A2 (pt) | 2021-04-21 | 2022-04-19 | Compostos de carbóxi-benzimidazol moduladores de glp-1r |
Country Status (15)
Country | Link |
---|---|
US (1) | US11858918B2 (pt) |
EP (1) | EP4271672A1 (pt) |
JP (1) | JP2024514009A (pt) |
KR (1) | KR20230173708A (pt) |
AU (1) | AU2022263410A1 (pt) |
BR (1) | BR112023021561A2 (pt) |
CA (1) | CA3216163A1 (pt) |
CL (1) | CL2023003119A1 (pt) |
CO (1) | CO2023013757A2 (pt) |
CR (1) | CR20230495A (pt) |
DO (1) | DOP2023000232A (pt) |
IL (1) | IL306110A (pt) |
PE (1) | PE20240362A1 (pt) |
TW (1) | TWI828119B (pt) |
WO (1) | WO2022225941A1 (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1102763E (pt) | 1998-08-07 | 2005-01-31 | Applied Research Systems | Mimeticos fsh para o tratamento da infertilidade |
AU2002337765A1 (en) | 2001-09-26 | 2003-04-07 | Bristol-Myers Squibb Company | Compounds useful for treating hepatitus c virus |
EP1628970A2 (en) | 2003-04-30 | 2006-03-01 | The Institutes of Pharmaceutical Discovery, LLC | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
US20060122222A1 (en) | 2004-11-18 | 2006-06-08 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids |
EP1838690A2 (en) | 2004-12-21 | 2007-10-03 | Devgen N.V. | Compounds with kv4 ion channel activity |
JP2009508835A (ja) | 2005-09-16 | 2009-03-05 | アロー セラピューティクス リミテッド | ビフェニル誘導体及びc型肝炎の治療におけるその使用 |
AU2007233179A1 (en) | 2006-03-31 | 2007-10-11 | Astrazeneca Ab | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
WO2008033455A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
CA2736970A1 (en) | 2008-09-12 | 2010-03-18 | Biolipox Ab | Pyrimidinone derivatives for use as medicaments |
WO2010046780A2 (en) | 2008-10-22 | 2010-04-29 | Institut Pasteur Korea | Anti viral compounds |
JP5739526B2 (ja) | 2010-06-24 | 2015-06-24 | 武田薬品工業株式会社 | ホスホジエステラーゼ(PDEs)阻害薬としての縮合複素環化合物 |
US8975235B2 (en) | 2011-03-20 | 2015-03-10 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
CN103059014B (zh) | 2011-10-21 | 2016-05-18 | 北京韩美药品有限公司 | 新型杂芳基氨基衍生物 |
US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
WO2016018701A1 (en) | 2014-07-28 | 2016-02-04 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
KR20160066490A (ko) | 2014-12-02 | 2016-06-10 | 주식회사 씨앤드씨신약연구소 | 헤테로사이클 유도체 및 그의 용도 |
WO2016118638A1 (en) | 2015-01-20 | 2016-07-28 | Merial Inc. | Anthelmintic compounds, compositions and method of using thereof |
US20170035881A1 (en) | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
ES2947636T3 (es) | 2016-03-16 | 2023-08-14 | Kura Oncology Inc | Derivados de tieno[2,3-d]pirimidina sustituida como inhibidores de menina-MLL y métodos de uso |
SI3438095T1 (sl) | 2016-03-30 | 2021-09-30 | Ishihara Sangyo Kaisha, Ltd. | Piridazinonska spojina ali njena sol in herbicid, ki jo vsebuje |
ES2934789T3 (es) | 2016-12-16 | 2023-02-27 | Pfizer | Agonistas del receptor glp-1 y usos del mismo |
EP3600327A4 (en) | 2017-03-27 | 2020-10-28 | Cardurion Pharmaceuticals, LLC | HETEROCYCLIC COMPOUND |
WO2019055540A1 (en) | 2017-09-13 | 2019-03-21 | D.E. Shaw Research, Llc | COMPOUNDS AS INHIBITORS OF RAS AND THEIR USE |
AU2019266114A1 (en) | 2018-05-08 | 2020-08-27 | Vtv Therapeutics Llc | Therapeutic uses of GLP1R agonists |
CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
PT3806855T (pt) | 2018-06-15 | 2023-05-03 | Pfizer | Agonistas dos receptores de glp-1 e suas utilizações |
WO2020033413A2 (en) | 2018-08-07 | 2020-02-13 | Tosk, Inc. | Modulators of ras gtpase |
PE20211871A1 (es) | 2018-11-22 | 2021-09-21 | Qilu Regor Therapeutics Inc | Agonistas de glp-1r y usos de los mismos |
US10954221B2 (en) | 2019-04-12 | 2021-03-23 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
EA202192684A1 (ru) | 2019-04-12 | 2021-12-28 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
CN112294760A (zh) | 2019-07-26 | 2021-02-02 | 张晋宇 | 一种液体制剂及其应用 |
WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
CA3157525A1 (en) | 2019-10-25 | 2021-04-29 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
KR20210053680A (ko) | 2019-11-04 | 2021-05-12 | 주식회사 엘지화학 | 광변조 디바이스의 제조 방법 |
KR102344561B1 (ko) | 2019-11-15 | 2021-12-29 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
EP4069686A4 (en) | 2019-12-02 | 2022-11-09 | Hyundai Pharm Co., Ltd. | GLP-1 RECEPTOR AGONIST |
EP4097097A1 (en) | 2020-01-29 | 2022-12-07 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2021155841A1 (en) | 2020-02-07 | 2021-08-12 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
CN115697999A (zh) | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
MX2022011349A (es) | 2020-03-18 | 2022-11-10 | Lg Chemical Ltd | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
WO2021191812A1 (en) | 2020-03-27 | 2021-09-30 | Pfizer Inc. | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
CA3179890A1 (en) | 2020-05-27 | 2021-12-02 | Qilu Regor Therapeutics Inc. | Salt and crystal forms of glp-1r agonists and uses thereof |
IL298753B2 (en) | 2020-06-04 | 2024-05-01 | Hangzhou Sciwind Biosciences Co Ltd | A pentavalent heteroaromatic imidazole compound and its use |
CN113816948B (zh) | 2020-06-19 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
AU2021327397A1 (en) | 2020-08-21 | 2023-05-04 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
CN115515956A (zh) | 2020-09-29 | 2022-12-23 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
MX2023006186A (es) | 2020-11-27 | 2023-08-07 | Shenzhen Salubris Pharm Co Ltd | Derivado de benzimidazol y método de preparación del mismo y uso médico del mismo. |
WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2022192430A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
CR20230493A (es) | 2021-04-21 | 2024-02-19 | Gilead Sciences Inc | Compuestos carboxi-benzimidazol moduladores de glp-1r |
CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
-
2022
- 2022-04-19 KR KR1020237039911A patent/KR20230173708A/ko active Search and Examination
- 2022-04-19 US US17/724,212 patent/US11858918B2/en active Active
- 2022-04-19 IL IL306110A patent/IL306110A/en unknown
- 2022-04-19 WO PCT/US2022/025364 patent/WO2022225941A1/en active Application Filing
- 2022-04-19 PE PE2023002895A patent/PE20240362A1/es unknown
- 2022-04-19 JP JP2023563841A patent/JP2024514009A/ja active Pending
- 2022-04-19 EP EP22723851.6A patent/EP4271672A1/en active Pending
- 2022-04-19 CR CR20230495A patent/CR20230495A/es unknown
- 2022-04-19 CA CA3216163A patent/CA3216163A1/en active Pending
- 2022-04-19 AU AU2022263410A patent/AU2022263410A1/en active Pending
- 2022-04-19 BR BR112023021561A patent/BR112023021561A2/pt unknown
- 2022-04-20 TW TW111114936A patent/TWI828119B/zh active
-
2023
- 2023-10-19 CL CL2023003119A patent/CL2023003119A1/es unknown
- 2023-10-19 CO CONC2023/0013757A patent/CO2023013757A2/es unknown
- 2023-10-19 DO DO2023000232A patent/DOP2023000232A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202302569A (zh) | 2023-01-16 |
US11858918B2 (en) | 2024-01-02 |
PE20240362A1 (es) | 2024-03-04 |
AU2022263410A1 (en) | 2023-10-05 |
IL306110A (en) | 2023-11-01 |
TWI828119B (zh) | 2024-01-01 |
CA3216163A1 (en) | 2022-10-27 |
DOP2023000232A (es) | 2023-11-30 |
JP2024514009A (ja) | 2024-03-27 |
CL2023003119A1 (es) | 2024-04-19 |
CO2023013757A2 (es) | 2023-11-10 |
EP4271672A1 (en) | 2023-11-08 |
CR20230495A (es) | 2023-11-30 |
WO2022225941A1 (en) | 2022-10-27 |
US20230102927A1 (en) | 2023-03-30 |
KR20230173708A (ko) | 2023-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022007627A2 (pt) | Compostos moduladores do glp-1r | |
BR112023021561A2 (pt) | Compostos de carbóxi-benzimidazol moduladores de glp-1r | |
BR112023021978A2 (pt) | Compostos de carbóxi-benzimidazol moduladores de glp-1r | |
BR112019022515A2 (pt) | Agentes de anticorpo direcionados contra o gene 3 de ativação linfocitária (lag-3) e usos dos mesmos | |
CR20140422A (es) | Composiciones de enzima digestiva estable | |
BR122020000059B8 (pt) | composição que compreende uma matriz biocompatível e um fator de crescimento derivado de plaqueta e kit | |
BR112022009938A2 (pt) | Compostos macrocíclicos substituídos e métodos de tratamento relacionados | |
BR112022005711A2 (pt) | Métodos e composições para tratar uma doença ou transtorno | |
ECSP21026021A (es) | Moduladores de la expresión de pnpla3 | |
BR112015020235A2 (pt) | fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit | |
BR112021024634A2 (pt) | Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno | |
BR112021017820A2 (pt) | Composições e métodos para modulação da atividade de complemento | |
PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
BR112022006016A2 (pt) | Métodos e materiais para tratar neurotoxicidade | |
WO2018189661A3 (en) | Methods and compounds for treating diabetes | |
AR117094A1 (es) | Moduladores de expresión irf5 | |
BR112019003816A2 (pt) | composição de tratamento de enxágue dos cabelos, método para tratamento de cabelos quimicamente danificados e uso de uma composição | |
UY38472A (es) | Moduladores de la expresión de foxp3 | |
CL2021000107A1 (es) | Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma | |
BR112021015222A2 (pt) | Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1 | |
BRPI0508497A (pt) | moduladores de canais de ìons e composição que os contém | |
PE20200749A1 (es) | Moduladores de la expresion de enac | |
TR200001724T2 (tr) | 5-HT1F Agonistleri | |
DOP2007000020A (es) | Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias |